Insight Molecular Diagnostics Inc. — Director's Dealing 2016

Feb 18, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2016-02-16

Reporting Person: Redmond Cavan M. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-02-16	Option to Purchase Common Stock	$3.06	A	20000	Acquired	2026-02-15	Common Stock (20000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option to Purchase Common Stock	$3.16	2025-09-08	Common Stock (10000)	10000	Direct

Footnotes

F1: Will become exercisable in four equal installments at the end of each calendar quarter based upon continued service on the board of directors from the date of grant.

F2: 2,500 options became exercisable on September 30, 2015 and December 31, 2015, and the remaining 5,000 options will become exercisable in 2 equal quarterly installments based upon continued service on the board of directors.